search icon
  • Print
  • ShareThis
  • Text Size

RSS Feed Print Category View
AbbVie Announces Positive Phase III Results
ThomasKim
Posted: Friday, April 11, 2014 1:52 PM
Joined: 2/20/2013
Posts: 40


"While AbbVie is widely expected to be the second entrant to the soon-to-explode market for hepatitis C cocktail drugs after standard-bearer Gilead Sciences, promising data from latecomer Merck have analysts relegating the Illinois company to third place despite some excellent late-stage results.

At this week's International Liver Congress in London, AbbVie is trumpeting stellar Phase III results from its three-drug combination, which posted 12-week cure rates upward of 96% in patients with hard-to-treat genotype 1 hep C and in those who've already failed to derive a benefit from previous treatment. The results, published in The New England Journal of Medicine, are part of AbbVie's expansive late-stage program in which it tracked more than 2,300 patients, and the data will support an application for FDA approval expected this quarter."

To read more,please visit: http://www.fiercebiotech.com/story/abbvie-angles-hep-c-spotlight-merck-shoulders-front/2014-04-11#ixzz2ybLJvK8P
 

| HIVMA | Contact Us

© Copyright IDSA 2014 Infectious Diseases Society of America

Full Site Mobile Site